Hematological Malignancies

Treatment Regimen for 131 I Tositumomab (Licensed in USA – no longer available)

Day 7–14 Day 0 Thyroprotection: Day -1 continuing through 14 days post-therapeutic dose

Therapeutic dose (450 mg tositumomab, mCi dose of 131 I tositumomab [35 mg] to deliver desired cGy TBD)

Dosimetric dose (450 mg tositumomab, 5 mCi 131 I tositumomab [35 mg])

Whole body counts x 3

• Unlabeled predose infused over 1 hour • Dosimetric dose used to determine individual pharmacokinetics

• Unlabeled predose infused over 1 hour • Administered mCi activity determined by gamma counts